Australis Capital Inc
Australis Capital Inc. operates as a cannabis company in the United States and internationally. The company was incorporated in 2018 and is based in Las Vegas, Nevada.
Australis Capital Inc (AUSAF) - Net Assets
Latest net assets as of March 2022: $45.59K USD
Based on the latest financial reports, Australis Capital Inc (AUSAF) has net assets worth $45.59K USD as of March 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($63.32K) and total liabilities ($17.73K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $45.59K |
| % of Total Assets | 72.01% |
| Annual Growth Rate | 93.09% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 43.33 |
Australis Capital Inc - Net Assets Trend (2017–2022)
This chart illustrates how Australis Capital Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Australis Capital Inc (2017–2022)
The table below shows the annual net assets of Australis Capital Inc from 2017 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-03-31 | $36.44 Million | -31.33% |
| 2021-03-31 | $53.07 Million | -8.14% |
| 2020-03-31 | $57.77 Million | -4.79% |
| 2019-03-31 | $60.67 Million | +37341.33% |
| 2018-03-31 | $-162.92K | -112.00% |
| 2017-03-31 | $1.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Australis Capital Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2103510000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2022)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $20.94 Million | 100.00% |
| Common Stock | $26.21 Million | 125.13% |
| Other Comprehensive Income | $36.44 Million | 173.98% |
| Total Equity | $20.94 Million | 100.00% |
Australis Capital Inc Competitors by Market Cap
The table below lists competitors of Australis Capital Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hanil Iron & Steel Co. Ltd.
KQ:002220
|
$26.61K |
|
Mobi724 Global Solutions Inc
PINK:MOBIF
|
$26.61K |
|
Sure-Tech Investments LP
TA:STEC
|
$26.64K |
|
Quantum D C Public Company Limited
BK:QDC
|
$26.64K |
|
CITIC SECURITIES-H-
MU:CI9
|
$26.60K |
|
HEMOGENYX PHARM.PLC LS-01
F:5HU
|
$26.58K |
|
CBRLAND PHARMA
BE:CBJ
|
$26.57K |
|
AdvancedAdvT Ltd
LSE:ADVT
|
$26.56K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Australis Capital Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 48,773,661 to 20,944,953, a change of -27,828,708 (-57.1%).
- Net loss of 50,088,992 reduced equity.
- Other comprehensive income increased equity by 19,740,430.
- Other factors increased equity by 2,519,854.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-50.09 Million | -239.15% |
| Other Comprehensive Income | $19.74 Million | +94.25% |
| Other Changes | $2.52 Million | +12.03% |
| Total Change | $- | -57.06% |
Book Value vs Market Value Analysis
This analysis compares Australis Capital Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | $0.01 | $0.00 | x |
| 2018-03-31 | $0.00 | $0.00 | x |
| 2019-03-31 | $0.64 | $0.00 | x |
| 2020-03-31 | $0.36 | $0.00 | x |
| 2021-03-31 | $0.28 | $0.00 | x |
| 2022-03-31 | $0.08 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Australis Capital Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -239.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -661.50%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 2.42x
- Recent ROE (-239.15%) is below the historical average (-56.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -2.93% | 0.00% | 0.00x | 1.05x | $-167.36K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-26.40K |
| 2019 | -6.87% | -3214.42% | 0.00x | 1.07x | $-10.24 Million |
| 2020 | -40.41% | -10539.01% | 0.00x | 1.10x | $-29.12 Million |
| 2021 | -51.79% | -3522.41% | 0.01x | 1.35x | $-30.14 Million |
| 2022 | -239.15% | -661.50% | 0.15x | 2.42x | $-52.18 Million |
Industry Comparison
This section compares Australis Capital Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Australis Capital Inc (AUSAF) | $45.59K | -2.93% | 0.39x | $26.60K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |